InflaRx N.V. (FRA:IF0)

Market Cap	51.45M -63.6%
Revenue (ttm)	62.84K -62.7%
Net Income	-40.10M
EPS	-0.62
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	740
Open	0.7410
Previous Close	0.7180
Day's Range	0.7410 - 0.7410
52-Week Range	0.6230 - 1.9760
Beta	n/a
RSI	45.03
Earnings Date	Mar 20, 2026

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company’s C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflamma...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2007
• Employees: 74
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: IF0

Financial Performance

In 2024, InflaRx's revenue was 165,789, an increase of 162.79% compared to the previous year's 63,089. Losses were -46.06 million, 7.96% more than in 2023.